drugset / Trial / NCT02248259

Drug Drug Interaction Trial With Strong CYP3A4 Inhibitor (Itraconazole) in CYP2C19 Extensive Metabolizers and Poor Metabolizers

NCT02248259

Phase 1 Completed 25 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

The objective of the current study is to evaluate the effect of once daily itraconazole on the pharmacokinetics of BI 409306 in poor (PM) and extensive metabolisers (EM) of CYP2C19.

Timeline

Start
2014-10-08
Primary completion
2015-01-07
Completion
2015-01-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Itraconazole Small molecule 200 mg Oral
Subject OSORESNONTRINE Small molecule 25 mg Oral

Indications

No indication recorded.